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2Preface
Infectious tropical diseases cause a huge toll in terms of mortality and 
morbidity, as well as a large economic burden to the countries concerned. These 
diseases predominantly affect the world’s poorest people. Unfortunately, current 
drugs are inadequate for the majority of these diseases, and there is an urgent need 
for new treatments. In this review, we discuss some of the challenges involved in 
developing new drugs to treat these diseases and highlight recent progress. Whilst 
there have been notable successes, there is still a long way to go.
1. Introduction
Infectious tropical diseases mainly affect Low and Middle Income Countries 
(LMICs). The symptoms range from impaired cognitive and physical development in 
children (Box 1), complications in pregnancy, fever, nausea, diarrhea, dehydration, 
anemia, rashes, lesions, deformities, blindness, organ failure, haemorrhaging, 
neurological problems, seizures and coma and in many cases death. In 2015 the 
WHO estimated that the diseases listed in Figure 1, were responsible for over 4 
million deaths1 and over 250 million years lost due to ill-health, premature disability 
or early death (DALYs – disability-adjusted life years)
2
.
Infectious tropical diseases include those defined by the World Health 
Organisation (WHO) as neglected tropical diseases (NTDs), listed by an asterisk in 
text below3. In addition, diseases such as malaria, tuberculosis (TB), HIV/AIDS, multi-
drug resistant Gram-negative bacterial infections, diarrhea (from a variety of 
pathogens), and hepatitis also disproportionately affect tropical countries. Whilst not 
an exhaustive list, the most common tropical diseases are: (i) viruses: chikungunya*,
dengue*, ebola, HIV-AIDS, Lassa fever, Marburg, rabies*, Rift Valley, yellow fever,
Zika disease. (ii) bacteria: bubonic plague, Buruli ulcer*, leprosy*, mycetoma*, 
shigellosis, trachoma*, TB, typhoid, typhus, yaws*, drug resistant Gram-negative 
bacteria. (iii) protozoa: Chagas’ disease*, cryptosporidiosis, human African 
trypanosomiasis*, leishmaniases* (visceral, cutaneous, post kala-azar dermal and 
mucocutaneous), malaria. (iv) fungi: cryptococcosis, mycetoma*. (v) helminths or 
metazoan worms: cysticercosis/taeniasis*, dracunculiasis*, echinococcosis*, 
foodborne trematodiases (clonorchiasis, opisthorchiasis, fasciolosis)*, lymphatic 
filariasis*, onchocerciasis*, schistosomiasis*, soil-transmitted helminthiasis*
(ascariasis, hookworm, trichuriasis, strongyloidiasis), guinea worm*. Co-infection is 
commonplace, and this can exacerbate symptoms and complicate treatments (Box 
32). 
Infectious tropical diseases inflict a high economic burden, costing LMIC 
economies billions of dollars every year. By way of example, it was estimated in 2013 
that the annual global cost of dengue was US$8.9 billion
4
, whilst a study in the 
Philippines indicated each case schistosomiasis resulted in an average loss of 45.4 
days of work per year5.
For many of these diseases the current treatments are unsatisfactory ande 
there are few or no suitable drugs. Without doubt, there is an urgent need for new, 
safe, low cost, efficacious medicines. Tackling these diseases effectively requires an 
integrated multi-sectoral approach, linking chemotherapy with prevention initiatives 
such as improved water supply, sanitation and hygiene, vaccines and vector control. 
Various governmental and non-governmental organisations, charities, foundations, 
product development partnerships, academic groups and pharmaceutical companies
support tropical disease drug discovery. A breakdown of funding is summarised in 
the G-Finder
6
 and IFPMA 2017
7
 reports. In 2014 about two-thirds of the total funding 
for research and development for neglected diseases as recorded by G-Finder
($3,377 million) was spent on HIV/AIDS (34%), malaria (18%) and TB (18%). Overall 
R&D funding has significantly increased in the last decade but gains are not shared 
equitably across diseases. Given the huge unmet medical need, greater effort, 
resources and funding are still required.
In this review, we will consider the specific challenges associated with tropical 
disease drug discovery and examine some of the recent successes. 
2. Discovery Pathways and Challenges
The drug discovery pathway
The pathway for a typical small molecule drug discovery programme for an 
infectious disease is shown in Figure 2. The first step is to identify chemical start 
points (Hit Discovery). This usually involves screening collections of compounds
against a molecular target, typically an enzyme (target-based screening) or against 
whole organisms (cell-based or phenotypic screening). Other hit discovery 
approaches include structure-based drug discovery, re-purposing of drugs from other 
disease areas, or in silico methods. Hit Expansion is carried out to verify that the hit is 
genuine and that there is scope for further work with the chemotype. The compound 
is then refined through a cyclic process of ‘design – make – test’ (Hits to Lead), until it 
4has significant activity in an animal model of infection. After this, the Lead 
Optimisation phase optimises and balances the biological activity, the 
pharmacokinetics and the safety profile of the series. Candidate Selection marks a
significant milestone in the early stage drug discovery pathway as it involves selecting 
one compound for progression. Regulatory toxicology and scale up are carried out to 
enable first in human studies. In human Clinical Trials, the compound is tested first in 
healthy volunteers to measure pharmacokinetics and safety (Phase I), followed by 
studies to establish efficacy (Phase II), and then large-scale efficacy and safety 
studies (Phase III).
Target Product Profiles and Compound Progression Criteria
Target Product Profiles (TPP) should guide the drug discovery pathway. They 
describe the desired features required of the final drug product, such as duration of 
treatment, whether the treatment is oral or parenteral, cost of treatment, acceptable 
safety margins, etc8. TPPs have been defined for malaria9, leishmaniasis
10
, human 
African trypanosomiasis
10
, Chagas’ disease11, cryptosporidiosis12 and dengue13, but are 
absent for many other diseases, hampering the drug discovery process. The TPP is 
used to develop Compound Progression Criteria, which informs the required disease-
specific profile of a compound at every step along the drug discovery process. These 
include for example, activities in particular assays, pharmacokinetic profiles, and 
selectivity parameters8. Medicines for Malaria Venture (MMV) has excellent 
examples of Compound Progression Criteria on their website.
Challenges
For many tropical infectious diseases, there is little or no precedent in 
developing small-molecule drugs, which is exacerbated by insufficient understanding 
of the pathogen biology. As a result, there are often no relevant cellular models or
predictive animal models of the human disease. There is often little or no data from 
clinically active molecules to help understand what profile a new drug should have 
with respect to activity in preclinical assays, animal models and its pharmacokinetic 
profile. The key issues facing researchers seeking to discover new drugs to treat 
tropical diseases, are summarised in Figure 2, and will be considered below.
Biology Challenges
There are very few well-validated molecular drug targets for tropical diseases, in 
5part due to a lack of understanding of the detailed biology of many of the pathogens. 
For example, the function of many proteins is unknown, or is only inferred from 
other organisms. Therefore a key challenge is selecting a suitable molecular target, to 
limit the risk of later failure
8
. Criteria to assist with selecting appropriate targets 
include essentiality, druggability, assayability and the opportunity for selectivity over 
host orthologues
8
. Even if a target complies with all these criteria, inhibitors 
frequently fail to demonstrate cell-based activity due to poor permeability, inability 
to compete with high substrate concentrations in cells or because the compounds 
cannot inhibit the target sufficiently to kill the pathogen. The deficiency of genetic 
tools for many disease-relevant organisms is a key reason why so little essentiality 
data is available. However, new technologies are emerging
14-16
, including
CRISPR/Cas9
17,18
, which offer the prospect of significantly increasing the number of 
validated targets available in the near future.
Large-scale cell-based (phenotypic) screening is currently a popular screening 
approach to identify new chemical start points, as it does not require prior 
knowledge of the molecular target19,20. Developing assays that have sufficient 
throughput to allow compound library screening that maintain relevance to disease 
pathophysiology is challenging, but helps to reduce attrition in in vivo models and 
ultimately the clinic21. As assays improve in relevance they usually become more 
complex requiring substantial resources both in terms of specialist equipment and 
staff to develop and run the assays. Other challenges can be the lack of robust in 
vitro culture systems (for example Cryptosporidium); the inherent safety challenges 
of handling disease-causing agents in bulk; the lack of standardisation between 
different laboratories working on the same organisms; and the use of lab-strains and 
cell lines rather than recent clinical isolates and primary cells21,22.
Existing animal models of these infections are often poorly representative of the 
human disease. For example in onchocerciasis (river blindness), the worm 
(Onchocerca volvulus) is only infective to primates; consequently related, but 
different, worm species are used in mice or cattle models. Human malaria does not 
infect rodents normally; however a SCID mouse model has been developed that can 
be infected by human falciparum malaria23. Work is also ongoing to develop a mouse 
model of human vivax malaria
24
. Most normal mouse models of TB do not replicate 
the human disease well, and the mice do not form the granulomas which are typical 
of human disease. Encouragingly progress is being made on developing animal 
models that more closely replicate human pathology25-27. 
Recent human clinical trials in Chagas’ disease with azoles, which inhibit the 
6enzyme CYP51, have not been successful. A mouse model has now been developed 
that can distinguish between benznidazole, known to have clinical efficacy and an 
azole (posaconazole) that does not28. Better differentiation at this preclinical stage 
should improve clinical trials success rates.
Quiescence and Dormancy
Dormant infections further complicate some diseases. In malaria, P. vivax and P. 
ovale can remain dormant (hypnozoites) in hepatocytes of the human host for weeks 
to years, causing relapse29. Latent tuberculosis with absence of clinical symptoms but 
a risk of progression to clinical disease is estimated to affect one third of the global 
population30. Recently dormancy has been identified in Trypanosoma cruzi
31
. 
Quiescent and dormant pathogens have reduced metabolism compared to actively 
dividing pathogens and can be less susceptible to drugs. Developing assays for these 
forms of the pathogens is problematic. To effectively treat and eliminate these 
diseases, the challenge is to develop new drugs that effectively tackle the reservoir of 
dormant and quiescent infections.
Chemistry Challenges
It is essential that the compound can be dosed appropriately, usually orally, and 
reach the region of the body where the pathogen is located. The physicochemical 
properties of a molecule, such as molecular weight, solubility, lipophilicity, charge, 
number of hydrogen bond donors and acceptors are key in achieving this.
In some cases, the penetration of the compounds into the pathogen is
problematic. For example, Gram-negative bacteria are surrounded by an outer-
membrane; compounds can penetrate this through porins, which tend to let in 
hydrophilic molecules. Molecules then have to traverse the cell membrane, a lipid 
bilayer, which requires compounds with a degree of lipophilicity. Therefore to 
penetrate into the cytoplasm, compounds probably need to have very defined 
chemical properties, likely to be more polar and charged than typical drugs32,33. 
Having penetrated to the cytoplasm, there is then a risk of being pumped out of the 
bacteria through efflux transporters. Other pathogens such as Trypanosoma cruzi, 
Chlamydia trachomatis, Mycobacterium tuberculosis and viruses spend the majority 
of their life-cycle inside human host cells, which may hamper drug access. Some even 
localise to extreme environments such as acidic intracellular organelles (Leishmania 
spp., Salmonella spp.) and necrotic granulomas (M. tuberculosis). In the latter case a 
significant challenge is drug penetration through non-vascularised lipid-rich caseum 
7to access the pathogen34. Other infections are localised at sites protected by a blood-
tissue barrier, such as the central nervous system (HAT, Cryptococcus neoformans, 
encephalitis/meningitis causing viruses/bacteria, Taenia solium) and eyes (Chlamydia 
trachomatis). To reach these sites drugs need to pass through endothelial cells 
without being immediately pumped back into the blood by P-glycoprotein35.
By nature of these diseases, the cost of treatment must be low. For malaria, the 
aim is to produce a treatment that costs less than US$1. To achieve this, a short and 
cheap chemical synthesis is required and complex formulations to counter issues 
such as poor solubility are precluded. Due to the lack of cold-chains in many regions, 
compounds are required that are stable over long periods of time at high 
temperatures (>40C) and high humidity. Finally, patient compliance is challenging, 
compounded by often minimal medical support. As a result, minimising the number 
of doses and complexity of dosing regimens is essential. For example, MMV is aiming 
for a single dose treatment for bloodstream malaria9.
Resistance
Drug resistance is a significant problem for most infectious diseases, in 
particular for viral, bacterial and apicomplexan infections
36-38
. Poor usage of 
treatments can accelerate the occurrence of resistance. The most notable example 
at the moment is antibacterial drug resistance. In humans, antibiotics are sometimes
taken when not required, or given at sub-therapeutic doses, potentially increasing
the proportion of resistant bacteria within a pathogen population. This problem is 
aggravated by the large amounts of antibiotics in the environment due to 
indiscriminate use in agriculture and aquaculture. 
In an attempt to slow down resistance, combination therapy is being adopted in 
many diseases. This has been particularly successful in HIV/AIDS where the 
resistance rate for single therapy39 is incredibly high. Combination treatment has also 
proved very effective in TB and malaria. Worryingly, in the case of malaria, resistance 
is now arising in Southeast Asia to artemisinin combination therapy, the mainstay for 
treatment38. There is a need for drugs with novel modes of action to deliver new 
combination therapies with no clinical resistance to any of the components of the 
therapy.
3. Progress
Despite all these challenges, progress is gradually being made. Some examples 
are highlighted below, although our coverage is not complete. The successes are due 
8to coordinated and substantial investment into research, along with concerted 
efforts to understand the TPPs and drug discovery pathways.
Apicomplexans
With 200 million cases of malaria a year, the human and economic cost of 
malaria is extremely high40. Africa carries a disproportionately high share of the 
burden with over 400,000 deaths a year. Multiple new types of antimalarial are 
needed to: overcome resistance; give single dose treatments; prevent relapse of P. 
vivax infections; block transmission; and act as chemopreventatives. The malaria 
drug discovery portfolio has dramatically improved over the past decade41. The 
starting points for the majority of the compounds currently in development were 
identified by phenotypic screening in collaborations with MMV. In many cases target-
deconvolution has subsequently led to the identification of the molecular targets.
There are a number of novel compounds in clinical trials supported by or in 
collaboration with MMV (Figure 3). The following are derived from phenotypic 
screens and in Phase II trials: the spiroindolone KAE609, the imidazolopiperazine 
KAF156
42
 (combination trial with lumefantrine), the synthetic trioxolane artefenomel 
(OZ439) in combinationwith ferroquine
43
 and the 2-aminopyridine MMV048. The 
mode of action has been determined for some of these (PfATP4 for KAE609
44
, 
PfPI(4)K for MMV048)
45
, while the mode of action of KAF156 and OZ439 remains
uncertain; KAF156 has been linked to cyclic amine resistance locus (Pfcarl)
46
 and 
OZ439 probably acts through formation of carbon radicals, whilst ferroquine acts to 
prevent heme detoxification. In Phase I trials are: the dihydroisoquinoline SJ733, 
which is another PfATP4 inhibitor
47
; and M5717 which is active against translation 
elongation factor 2
48
. Two compounds derived from target-based projects are also in 
clinical trials: the dihydroorotate dehydrogenase inhibitor DSM265
49
, which is in
Phase II trials, and P218, a dihydrofolate reductase inhibitor, which is in Phase I trials.
We envisage an increase in target-based drug discovery as mode-of-action 
studies are revealing the chemically validated targets of many of the recently 
identified phenotypic hits. A consortium led by Winzeler is systematically trying to 
find the mode of action of phenotypic hits
50
. Recently, new types of phenotypic 
screens have been developed which target life-cycle stages in addition to or other 
than the asexual blood stages51,52. Clinical development for malaria has accelerated 
thanks to the development of human challenge models in which healthy volunteers 
are infected with treatable malaria to obtain an early indication of drug efficacy53,54.
Cryptosporidiosis has been shown to be a major cause of diarrhea in children in 
9tropical countries (Box 1). Nitazoxanide, the current treatment for the disease, has 
variable efficacy in immunocompetent patients and is not effective in 
immunocompromised patients55,56. There is an urgent need for the development of 
new drugs to treat children under 24 months, especially those that are malnourished 
and suffering from chronic diarrhea. 
There have been recent advances in the cryptosporidiosis discovery pipeline. A 
series of bumped kinase inhibitors of Cryptosporidium parvum calcium-dependent 
kinase 157, an example of which is BKI1534, has been developed. Promisingly, recent 
advances in C. parvum high-content imaging infection assays in human intestinal 
epithelial cells have made phenotypic screening of medium and large size compound 
libraries possible. A screen of compounds active against malaria has led to the 
identification of a preclinical candidate KDU73158, an inhibitor of Cryptosporidium
phosphatidylinsoitiol 4-kinase. Clofazimine, an approved drug for the treatment of 
leprosy, was identified from a screen of bioactive compounds59 and is entering clinical 
trials for cryptosporidiosis.
Kinetoplastid diseases
We have recently reviewed this area in detail60. Mortality rates for human 
African trypanosomiasis (HAT/Sleeping Sickness) have decreased substantially in 
recent years61, but there is still a significant disease burden in central Africa. The 
advent of NECT (nifurtimox-eflornithine) combination therapy in 2009 marked an 
important step in the treatment for stage 2 T. b. gambiense HAT. It reduced the 
duration of treatment as well as decreasing adverse effects62. Nevertheless, 
treatment is still problematic because the two forms of the disease (T. brucei 
gambiense / T. b. rhodesiense) and the two stages (acute / CNS) require different 
drugs61. The requirement for staging patients prior to treatment also limits uptake, as 
it involves a painful and technically challenging lumbar puncture63. The on-going 
development of two new drugs has the potential of transforming the clinical 
management of HAT64. The first is fexinidazole, a nitroaromatic compound developed 
in the 1970s and 1980s as a broad-spectrum antibiotic, was more recently found to 
have a suitable profile for clinical development for HAT65. Drugs for Neglected 
Diseases initiative (DNDi) completed a Phase III clinical trial in 2017 and reported non-
inferiority over NECT for both stages of the disease with a 10-day oral treatment66. 
The second is an oxaborole compound, SCYX-7158 (acoziborole)67, currently 
undergoing a pivotal Phase II/III trial
10
. This has potential to give a single dose oral 
10
treatment for all forms of HAT.
For leishmaniasis and Chagas’ disease, less progress has been made. In the 
Indian subcontinent, current treatments, particularly liposomal amphotericin-B, 
together with other measures such as vector control and effective surveillance, may 
offer the possibility of elimination of visceral leishmaniasis (VL)
68
. However, the 
current drugs are less effective or unsuitable in other areas of the world. New oral 
drugs are urgently needed to treat VL in these regions and to provide improved 
treatment options in the Indian sub-continent. HIV-VL coinfection is also poorly 
treated. Several oral treatments identified through phenotypic screening are in
preclinical development. These include an oxaborole and a nitroimidazole69. Notably
the discovery of a pan-kinetoplastid proteasome inhibitor (GNF6702, Fig. 3)70 offers 
potential for development of new drugs for leishmaniasis, Chagas’ disease and HAT. 
The majority of leishmaniasis preclinical work focuses on VL, the deadly form of the 
disease, rather than cutaneous leishmaniasis (CL). New oral therapies are urgently 
needed for CL as well. Chagas’ disease research suffered a recent setback resulting 
from the clinical failures for the CYP51 inhibitors posaconazole and 
fosravuconazole71,72. Currently, the pipeline for this challenging disease is sparse.
Viruses
Viruses such as HIV, hepatitis C (HCV), dengue and rabies have significant global 
impact (Figure 1) resulting in over 1 million deaths in 2015 (WHO 2015). Effective 
treatments for HIV and HCV have been developed73,74. Other viruses, including 
flaviviruses, arenaviruses, coronaviruses and filoviruses still pose a significant threat 
for tropical countries and beyond with a particular risk for global pandemics; as 
exemplified by the recent outbreaks of Zika75, chikungunya76, dengue77, ebola78 and 
MERS79. Since future epidemics are almost inevitable, and could be triggered by any 
member of these families, drug discovery efforts rightly focus on broad-acting 
antivirals80. In terms of small-molecule drug discovery, these diseases have received 
relatively little attention. However, both target and cell-based hit discovery 
approaches have yielded new compounds of interest, but to date none of these have 
progressed anywhere as far as the HCV and HIV drugs80. The most advanced 
compounds are favipiravir, GS-5734 (remdesivir) and BCX4430 (galidesivir) that 
target the viral polymerase (Fig. 3). Favipiravir was tested in humans during the ebola 
virus epidemic of 2014, and while conditions complicated the study, it was concluded 
that further investigation was warranted81. GS-5734 has shown activity in a rhesus 
monkey model of Ebola
82
, and was also used in humans during the 2014 Ebola 
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outbreak. It is currently undergoing a phase II clinical trial in West Africa. Both 
favipiravir and GS-5734 are being considered for use in the 2018 Ebola virus outbreak 
in the Democartic Republic of the Congo
83
. BCX4430 has demonstrated complete 
protection against Marburg virus in non-human primates and against Ebola in rodent 
models, when administered within 48h of infection. This compound also shows broad 
activity against other viruses including arenaviruses and flaviviruses84,85 and is 
currently in clinical development. Inhibitors targeting the viral protease are not as far 
advanced (with the exception of HIV and HCV). They also show promise as broad-
spectrum antivirals. The potential of targeting host pathways is also being 
explored80,86. While new small-molecule antivirals are being discovered, there clearly 
is an urgent need to translate more of them into the clinic, alongside on-going 
vaccine development.
Bacterial diseases
Tuberculosis continues to be a major problem across the world. As with malaria, 
treatments for TB are given as combinations to combat resistance, and can 
circumvent issues with TB residing in multiple environments and metabolic states.
The need for combination therapy complicates the progression of new compounds 
through clinical trials87. Recently two new drugs, bedaquiline and delaminid, have 
conditionally approved for the treatment of specific levels of drug-resistant TB on the 
basis of phase IIb trials and are currently undergoing phase III studies88. Bedaquiline 
targets the ATP synthase89 and is active against the latent forms of the bacterium90. 
Delamanid is a nitro-heterocycle. Its precise mode of action has not been 
determined, but it is probably a prodrug that needs activation within the bacterium. 
It has been implicated in inhibition of mycolic acid biosynthesis; which is critical for 
the structure of M. tuberculosis cell wall
91,92
.
A number of other compounds are currently under development for TB87,93 that 
target protein synthesis, the respiratory chain and the cell envelope. Several different 
steps in protein synthesis are being studied. Recently, linezolid has been shown to be 
active against drug-resistant TB, and has significant effect on patients with 
extensively drug-resistant TB94. This is one of the oxazolidinone class of molecules 
which targets the 50S ribosomal subunit. However, adverse effects are associated 
with the extended treatment periods with linezolid that are required for multi-drug-
resistant TB. This is linked to mitochondrial toxicity
95
. Other oxazolidinones, such as 
sutezolid and delpazolid are undergoing clinical trials88. Avoiding mitochondrial 
toxicity should allow development of compounds with better tolerability. A 
12
collaboration between Anacor and GSK, has given rise to a series of oxaboroles96. 
One of these compounds GSK070, which inhibits leucyl-tRNA synthetase, an enzyme 
involved in protein synthesis, is being progressed in clinical trials. The compound 
forms a covalent adduct with the 3’-adenosyl acceptor nucleotide of the tRNA, with 
the boron binding to the 2’- and 3’-hydroxyl groups. This complex is formed in the 
editing site, inactivating the enzyme.
Q203 has just entered clinical trials and targets the respiratory pathway, 
inhibiting cytochrome bc1 (QcrB)
89
. This is on the same pathway targeted by 
bedaquiline, although at a different step. Hitting this pathway at multiple points 
appears to enhance killing of the bacterium89.
In terms of cell wall biosynthesis, -lactams are also being re-investigated for 
TB. Carbapenems appear to be the more attractive compounds, both from the 
proteins that they target and also as they are much weaker substrates of the M. 
tuberculosis -lactamases. Several enzymes involved in cell envelope biosynthesis 
are promiscuous targets; DprE1 and MmpL3. The former is involved in the 
biosynthesis of an arabinogalactan polysaccharide which is critical for cell wall 
biosynthesis. Benzothiazones have been discovered to be covalent inhibitors of this 
enzyme; one of these compounds, BTZ043, is in preclinical development and 
another, PBTZ169 is undergoing clinical evaluation
93
. Two non-covalent inhibitors of 
DprE1 are also undergoing clinical evaluation, both in phase I, an azaindole TBA-7371 
and OPC-167832. MmpL3 is required for the export of mycolic acid precursors, which 
are essential for cell wall biosynthesis. Compound SQ109 which targets this enzyme, 
and probably others
88
, is in clinical trials97. InhA, which is an enoyl reductase and part 
of the fatty acid biosynthesis pathway, is involved in the biosynthesis of mycolic acid. 
Isoniazid is a prodrug, which when activated inhibits InhA, validating InhA as a drug 
target. Several preclinical drug discovery programmes are on-going to find direct 
inhibitors of InhA.
Pretomanid (PA-824) is a nitroimidazole which is in clinical trials. This compound 
is active against both replicating and non-replicating mycobacteria. This is probably a 
prodrug like delamanid. A number of other compounds
98
 are undergoing clinical 
evaluation
93
, and several fluoroquinolines are being investigated as part of 
combinations, including moxifloxacin and levofloxacin. 
Whilst antibacterial drug resistance is not technically a neglected or tropical 
disease, the impact is most clearly seen in LMICs, which have very high levels of drug 
resistance. The WHO has recently published a priority list of pathogens99. The priority 
1 pathogens are: Enterobacteriaceae which are resistant to carbapenems and 3
rd
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generation cephalosporins and Acinetobacter baumannii and Pseudomonas 
aeruginosa that are carbapenem-resistant. New drugs are urgently needed to tackle 
these diseases, but there is very little in clinical development that addresses the most 
urgently needed cases100. In addition to this there are bacterial infections such as 
shigellosis and typhoid, which are almost entirely found in LMICs. Drug resistance is a 
major issue here and worryingly in some cases, the resistant bacteria have a higher 
fitness than wild type bacteria101,102. Treatment is reliant on existing antibacterials.
Helminths
At least one billion people, and probably more, are estimated to have one or 
more helminth infection
103
. Yet the only new antihelminthic drug to emerge in the 
last 30 years is tribendimidine, which shows promising broad-spectrum activity. 
Recent clinical trials demonstrated that it is a suitable alternative for the 
benzimidazoles and praziquantel in various helminth infections104-106. Beyond this, 
development of new treatments is focused on repurposing drugs. This has mostly 
involved anthelminthics approved for veterinary use. Oxantel pamoate, a veterinary 
licensed drug since 1974, has recently shown promising efficacy results in clinical 
trials for trichuriasis (whipworm), one of the more difficult to treat soil-transmitted 
helminths107, and in combination with albendazole and pyrantel pamoate, it has 
recently demonstrated high clinical efficacy against hookworm infections
108
. Two 
other veterinary drugs, emodepside and moxidectin, have promising activity against 
several human helminths and are currently undergoing clinical trials for 
onchocerciasis69,109. Some antimalarial compounds show activity against schistosomes 
in vitro and in vivo. Mefloquine-praziquantel and mefloquine-artesunate-
praziquantial combinations were tested in clinical trials against chronic S. 
haematobium infection. Unfortunately, adverse event rates were high while there 
was no increased efficacy compared to praziquantel110. In the case of filarial worms, 
an alternative strategy is targeting the Wolbachia endosymbiotic bacteria, which 
results in slow killing of the worms hereby preventing serious adverse events. Four 
weeks of treatment with doxycycline cures people suffering from onchocerciasis. The 
major aim of Wolbachia-directed therapy is to find shorter course antibiotics111. To 
discover new chemical entities for helminth infections several high-throughput 
phenotypic screens have been carried out112,113 but currently no new clinical 
candidates have been reported.
Fungal Infections
14
Fungal infections are particularly serious in immunocompromised patients. In 
addition to the common fungal infections, there are some fungal infections which are 
mainly found in tropical regions. One of the most significant problems is meningitis 
due to Cryptococcus neoformans, estimated to cause 180,000 deaths per year 
amongst HIV-infected people, the majority of whom are in Africa114. This is poorly 
treated and there is a need for new more efficacious drugs. Mycetoma, a disfiguring 
infection of the skin and soft tissue, is a particularly neglected disease endemic to 
tropical and subtropical areas. Mycetoma can be caused by bacteria 
(actinomycetoma) or by fungi (eumycetoma). Fungal mycetoma requires long 
treatment with azoles, but drug resistance, disease recurrence and side effects are
common. Patients often develop deformities requiring amputations. DNDi are 
currently running a Phase II/III trial for fosravuconazole to assess if this azole is more 
effective and safer than the currently used azoles itraconazole and ketoconazole. A 
comprehensive review of the current antifungal pipeline has recently been 
published115.
5. Conclusion
The current treatments used for tropical diseases are sub-optimal or in some 
cases there are no drugs available. However, recent progress in drug discovery in 
human African trypanosomiasis, TB and malaria show that with concerted efforts of 
governments, charities, foundations, product development partnerships, academic 
institutions and pharmaceutical companies, headway can be made. There is still a 
long way to go, even in these disease areas. The high attrition rate in clinical trials 
and issues of resistance means that there is no room for complacency. Further, 
multiple new agents are required for each disease area to allow combination 
therapies. Whilst there is progress in some disease areas, in other disease areas, 
there is much less support and activity. 
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Figure 1: Deaths and Disability Adjusted Life Years (DALYs) of selected tropical 
diseases from WHO Cause Specific Mortality (2015)
1
 and WHO Disease Burden 
(2015)
2
. Diarrheal diseases, tuberculosis, HIV/AIDS, malaria and hepatitis are shown 
separately as they have a much larger impact. Data is shown by WHO region.
Figure 2: Upper panel: The stages of the drug discovery process. Middle panel: 
generic challenges. Bottom panel: key challenges at particular stages of the drug 
discovery process.
Figure 3: Key compounds discussed in the text
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Box 1: Infants and Children
Many of the infectious tropical diseases disproportionately affect infants and 
children. In the case of malaria, the majority of deaths occur in children under the 
age of 5, as they are immune-naïve. Diarrhea is a major problem amongst children, 
causing hundreds of thousands of deaths per year. The Global Enteric Multicenter 
Study (GEMS), a case-control study conducted at 7 sites in Africa and South Asia, is 
the most comprehensive study of childhood diarrhea to date116,117. The most common 
pathogens found on this study were Shigella spp, rotavirus, adenovirus 40/41, heat-
stable enterotoxin-producing E. coli, Cryptosporidium spp and Campylobacter spp. In 
some cases mixed infections were a problem. Some tropical diseases are also 
associated with malnutrition, growth stunting and impaired cognitive development 
amongst children, for example cryptosporidiosis, schistosomiasis and soil transmitted 
helminths118,119. In addition, the drug discovery pathway for infants and children is 
complicated. Pharmacokinetics are much more difficult to predict in infants and 
children and additional safety testing is required, making clinical trials challenging. 
Further, ethical regulations in clinical trials for children are more complex.
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Box 2: Co-infections
Co-infections are associated with high prevalence and the extensive geographic 
overlap of some of these diseases. Someone who is already infected with one 
pathogen in some cases, may have an increased infection risk with another 
pathogen118. Some of the issues around co-infection are:
Co-infections frequently accelerate disease progression and outcomes as one 
disease enhances the effect of another. For example, malaria infection 
increases the viral load of HIV-infected patients, also making it easier for that 
person to pass on the HIV virus120. HIV-TB co-infection is particularly 
problematic; HIV weakens the immune system allowing latent TB to become 
activated and progress more rapidly. In turn, TB also accelerates the 
progression of HIV infection121.
Co-infections can result in complications in pregnancy and impair growth and 
development in children. For example, co-infections of malaria and hookworm 
can lead to severe depletions in haemoglobin resulting in severe anaemia122. 
Co-infections can complicate treatments due to drug-drug interactions which 
can affect efficacy and can give rise to cumulative drug toxicities producing 
adverse side effects123. This is a particular problem in HIV-TB co-infection.
Rifampicin, which is commonly used to treat TB, causes induction of 
cytochrome P450s. The latter metabolise some of the more commonly used 
anti-HIV drugs124. This means careful selection of treatments is required.
Co-infections can affect how diseases are treated. For example, ivermectin 
treatment for onchocerciasis may induce severe adverse reactions in some 
individuals heavily infected with Loa loa125,126. 
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